Search

Simulations Plus Inc

Suletud

SektorTervishoid

18.3 -0.11

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.29

Max

18.3

Põhinäitajad

By Trading Economics

Sissetulek

-960K

3.6M

Müük

-2.4M

22M

P/E

Sektori keskmine

45.775

68.51

Aktsiakasum

0.3

Kasumimarginaal

16.335

Töötajad

212

EBITDA

-6.3M

1.1M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-5.84% downside

Turustatistika

By TradingEconomics

Turukapital

-857K

370M

Eelmine avamishind

18.41

Eelmine sulgemishind

18.3

Uudiste sentiment

By Acuity

50%

50%

151 / 340 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

7. aug 2026, 23:56 UTC

News

Sweetgreen shares declined in after-market trading as multiple analysts lowered price targets, with UBS and RBC both setting targets at $6.50.

7. aug 2026, 23:46 UTC

News

JetBlue Airways reports wider net loss and updates operating guidance. Shares are lower in after-market trading following the $121.4 million shelf registration.

7. aug 2026, 23:46 UTC

News

Etsy Inc shares are lower in after-market hours following its Q2 results, which showed a double beat but faced revenue challenges from divestments.

7. aug 2026, 23:46 UTC

News

Cogent Communications is trading lower in after-market hours amid a class action lawsuit alleging securities fraud by Pomerantz LLP and ongoing operational challenges.

7. aug 2026, 23:41 UTC

News

ResMed shares declined after-market despite RBC Capital raising its price target to $244 and maintaining a Sector Perform rating.

7. aug 2026, 23:41 UTC

News

Mitek Systems reported an 18% revenue increase in Q3, with shares advancing in after-market hours, despite earlier pulling back from a session high.

7. aug 2026, 23:36 UTC

News

Tripadvisor Inc announced participation in two investor conferences, enhancing engagement with investors. Shares are trading slightly higher in after-market hours.

7. aug 2026, 23:36 UTC

News

Shift4 Payments lowers 2026 outlook, adjusting full-year revenue guidance down by about 200 basis points. Shares are trading lower in after-market hours.

7. aug 2026, 23:36 UTC

News

Epam Systems shares are trading lower in after-market hours following TD Cowen's price target cut to $120, despite earlier gains in the session.

7. aug 2026, 23:31 UTC

News

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

7. aug 2026, 23:31 UTC

News

Figs Inc reported strong Q2 earnings but is trading lower in after-market hours as Telsey Advisory Group lowered its price target to $16.

7. aug 2026, 23:31 UTC

News

Ardelyx shares are higher in after-market trading as TD Cowen maintains a Buy rating and lowers the price target to $10.

7. aug 2026, 23:31 UTC

News

Celsius Holdings is under investigation for potential securities law violations following disappointing second-quarter results, with shares trading lower in after-market hours.

7. aug 2026, 23:26 UTC

News

Delta Air Lines is gaining after reporting strong second-quarter results and positive passenger traffic growth projections, with anticipated earnings of $6.63 per share.

7. aug 2026, 23:26 UTC

News

Five9 Inc. reported second-quarter earnings of $0.70 per share and raised full-year revenue guidance to $1.27 billion. Shares are higher in after-market trading.

7. aug 2026, 23:26 UTC

News

UBS raised its price target on Unity Software Inc. to $48, contributing to shares trading higher in after-market hours. Positive sentiment from tech stocks also supported this move.

7. aug 2026, 23:26 UTC

Event
News

Scholar Rock Holding Corp reports FDA review progress for apitegromab, with a decision expected by September 30, 2026. Shares are trading higher in after-market hours.

7. aug 2026, 23:26 UTC

News

Kraft Heinz Co reported second-quarter revenue of $6.26 billion, exceeding expectations. Shares rose in after-market trading amid positive sentiment and broader market strength.

7. aug 2026, 23:26 UTC

News

Leidos Holdings shares are lower in after-market hours after TD Cowen raised the price target to $135 while maintaining a Hold rating.

7. aug 2026, 23:21 UTC

News

MP Materials will participate in Canaccord Genuity's Growth Conference in August 2026. Shares are trading higher in after-market hours following the announcement.

7. aug 2026, 23:21 UTC

News

TD Cowen raised its price target on Akamai Technologies to $140 while maintaining a Hold rating. Shares are higher in after-market trading.

7. aug 2026, 23:21 UTC

Social Media
News
Event

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

7. aug 2026, 23:21 UTC

News

Halozyme Therapeutics reported strong Q2 earnings and raised guidance, yet shares are trading lower in after-market hours following notable weakness.

7. aug 2026, 23:16 UTC

News

Hawaiian Electric Industries reported Q2 revenues of $939.70 million, but adjusted EPS of $0.13 missed estimates by $0.06. Shares are trading roughly flat in after-hours.

7. aug 2026, 23:16 UTC

News

10X Genomics Inc shares are lower in after-market trading amid a sector decline. Citigroup raised its price target to $50 while maintaining a Neutral rating.

7. aug 2026, 23:11 UTC

News

Ashland Inc. is exploring a potential sale amid takeover interest, while announcing a quarterly cash dividend of $0.42 per share. Shares lower in after-market trading.

7. aug 2026, 23:06 UTC

News

Baker Hughes reported a stable U.S. rig count of 588, with oil rigs rising to 454 and gas rigs declining to 124. Shares were little changed in after-market trading.

7. aug 2026, 23:06 UTC

News

Kimberly-Clark Corp shares are lower in after-market trading, reflecting ongoing challenges with revenue and margins amid rising input costs and competition.

7. aug 2026, 23:06 UTC

News

Photronics Inc shares are lower in after-market trading following a class action lawsuit alleging misleading statements about its product pipeline and demand stability.

7. aug 2026, 23:06 UTC

News

Morgan Stanley shares are lower after-market, reflecting a slight decline. The movement follows the bank's $400 million Bitcoin purchases amid uncertain market conditions.

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

-5.84% langus

12 kuu keskmine prognoos

Keskmine 17.25 USD  -5.84%

Kõrge 18.5 USD

Madal 16 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

0

Osta

4

Hoia

0

Müü

Sentiment

By Acuity

151 / 340 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat